title: The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
abstract: Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regimens containing TDF and ddI 250 mg were significantly better tolerated than combinations with TDF and ddI at a dose of 400 mg. Low-dose ddI 250 mg once daily plus TDF as part of antiretroviral therapy was effective.
authors.affiliation: St. Stephens Centre, Chelsea and Westminster Hospital, London, UK. Mun-Yee.Tung@chelwest.nhs.uk
authors.forename: M-Y
authors.initials: MY
authors.lastname: Tung
authors.forename: S
authors.initials: S
authors.lastname: Mandalia
authors.forename: M
authors.initials: M
authors.lastname: Bower
authors.forename: B
authors.initials: B
authors.lastname: Gazzard
authors.forename: M
authors.initials: M
authors.lastname: Nelson
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D000068698:Tenofovir; D017211:Treatment Failure; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine